The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
about
2-deprenyl-rheediaxanthone B isolated from Metaxya rostrata induces active cell death in colorectal tumor cellsBevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.Bacterial immunotherapy of gastrointestinal tumors.A new microarray substrate for ultra-sensitive genotyping of KRAS and BRAF gene variants in colorectal cancer.Comparative analysis of radiosensitizers for K-RAS mutant rectal cancersPrediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibitionAlternate dosing of cetuximab for patients with metastatic colorectal cancer.Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor.Recently identified and potential targets for colon cancer treatment.Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies.Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.Immunotherapy of colorectal cancer: new perspectives after a long path.EphrinA5 suppresses colon cancer development by negatively regulating epidermal growth factor receptor stability.Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts.Rapid detection of low-abundance K-ras mutation in stools of colorectal cancer patients using chip-based temperature gradient capillary electrophoresis.Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors.
P2860
Q28533805-CD24A411-16D2-43A2-A108-8947CC577BD6Q30884552-D49BAA3C-75A7-464B-B8C2-A3DBDC02B60DQ33418889-8F0A3F54-FD11-4714-9CE2-C51C774B9D40Q34242204-A7F13A55-813B-467E-A702-8CC7DF11D286Q34639858-A3F73953-04AD-44B1-BC19-03E5F8DA2D9BQ35070685-C47651A7-8F48-4ACE-8298-D09C4505FB39Q36516784-8035B4E0-1F42-479B-94DE-1DB2A4AC9AB4Q36907279-0F594D7B-9475-4905-BDAB-667A4A794EA9Q37732381-3B961BF0-65A8-4CEA-873D-CC12ED7EAB5DQ37763104-9BC29E1C-935F-46CD-8706-BB060C27B1D2Q37972865-9F5A0C5D-08E8-4994-9C5C-7765E7E90683Q38390840-EB796461-55DF-46CF-AF80-6D9A961A0A98Q39043413-AC04BBBF-D44D-411E-8421-41EA1BE39E21Q39445033-4B8F7C1F-4F1E-468C-B402-2EE17FF758F8Q39516903-02A47860-BA5E-4345-91E2-4719CC34C640Q39606707-8B6D9F4E-F3AF-4B4F-BE51-225E53DFDCE9Q42014039-477514F4-119C-44D2-8812-C68B4D5B4003Q45046519-99DAAA58-7CFE-4F59-B458-AF714CCA9243
P2860
The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The evolving role of monoclona ...... on clinical trial development.
@ast
The evolving role of monoclona ...... on clinical trial development.
@en
type
label
The evolving role of monoclona ...... on clinical trial development.
@ast
The evolving role of monoclona ...... on clinical trial development.
@en
prefLabel
The evolving role of monoclona ...... on clinical trial development.
@ast
The evolving role of monoclona ...... on clinical trial development.
@en
P2860
P1433
P1476
The evolving role of monoclona ...... on clinical trial development.
@en
P2093
P2860
P356
10.1634/THEONCOLOGIST.2009-0167
P577
2010-01-12T00:00:00Z